When a Pap smear shows atypical glandular cells and endometrial malignancy is a consideration, which diagnostic test is used to evaluate for endometrial pathology?

When a Pap smear shows atypical glandular cells and endometrial malignancy is a consideration, which diagnostic test is used to evaluate for endometrial pathology?

• A. Hysteroscopy
• B. Pelvic ultrasound
• C. CT scan
• D. Colposcopy with endocervical curettage

Answer: (D)

When atypical glandular cells are seen on a Pap smear and endometrial malignancy is a concern, you need tissue from the endometrium to confirm or exclude pathology. The most direct and informative approach is hysteroscopy with endometrial sampling. Hysteroscopy allows you to look inside the uterine cavity and perform targeted biopsies of any suspicious areas, increasing the likelihood of detecting hyperplasia or carcinoma, including focal lesions that might be missed with blind sampling. Endocervical curettage, which samples only the endocervical canal, does not assess the endometrium itself and therefore cannot reliably evaluate for endometrial pathology. Pelvic ultrasound can assess endometrial thickness and uterine structure noninvasively, which helps in risk stratification, but it does not provide a definitive diagnosis. Colposcopy examines the cervix and vaginal epithelium, not the endometrium, and CT is typically used for staging if cancer is already suspected, not for initial evaluation of endometrial pathology. So, the test that best evaluates the endometrium in this context is hysteroscopy with endometrial sampling.

When atypical glandular cells are seen on a Pap smear and endometrial malignancy is a concern, you need tissue from the endometrium to confirm or exclude pathology. The most direct and informative approach is hysteroscopy with endometrial sampling. Hysteroscopy allows you to look inside the uterine cavity and perform targeted biopsies of any suspicious areas, increasing the likelihood of detecting hyperplasia or carcinoma, including focal lesions that might be missed with blind sampling.

Endocervical curettage, which samples only the endocervical canal, does not assess the endometrium itself and therefore cannot reliably evaluate for endometrial pathology. Pelvic ultrasound can assess endometrial thickness and uterine structure noninvasively, which helps in risk stratification, but it does not provide a definitive diagnosis. Colposcopy examines the cervix and vaginal epithelium, not the endometrium, and CT is typically used for staging if cancer is already suspected, not for initial evaluation of endometrial pathology.

So, the test that best evaluates the endometrium in this context is hysteroscopy with endometrial sampling.